Item:
Title
Board Approval - To Consider Allocating Economic Development Funds to Adverum
Body
Date of BOCC Meeting: February 22, 2021
Request for Board Action:
Agenda Text
The Board was requested to hold a public hearing at the February 8, 2021 Regular Session meeting to consider allocating a total of $653,000 to Adverum. There was one public comment received during the 24hr public comment period which ended on February 9, 2021.
The Board was also requested to authorize the County Manager to enter into preliminary negotiations and execute an agreement with the Company. The Company, which specializes in Gene Therapy production, will locate in Durham County, creating 202 jobs and investing $82.8 million.
Adverum Biotechnologies is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. The Redwood City, Calif.-based biotechnology company is developing its lead gene therapy candidate ADVM-022 in ongoing clinical trials for wet age-related macular degeneration (AMD) and diabetic macular edema (DME). ADVM-022 is administered as a potential one-time, intravitreal injection for the treatment of wet AMD and DME, ocular diseases that impact millions of patients worldwide.
With approval of the award, the Company has agreed to make reasonable efforts to participate in several workforce partnerships that include engagements with Durham Public Schools Career and Technical Education, Durham Technical Community College and North Carolina Central's University. Please find additional project details including a full list of partnerships, terms and project attributes in the briefing sheet attached to the agenda item.
Adverum Biotechnologies' new presence in North Carolina will be facilitated, in part, by a Job Development Investment Grant (JDIG) approved by the state's Economic Investment Committee on January 7th. Over the 12-year life of the grant, the project is estimated to grow the state's economy by nearly $1....
Click here for full text